120 results about "Intramuscular injection" patented technology

The invention relates to a method for stimulating an immune response by intramuscular injection of an artificial nucleic acid molecule comprising an open reading frame encoding an antigen and a 3′-UTR comprising at least two poly(A) sequences. The method may yield an increased immune response to the antigen or an increased neutralizing antibody response to the antigen.

The invention discloses mannheimia haemolytica outer membrane vesicles as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The OMV is separated from Mh-5 strain culture supernatant through tangential flow ultrafiltration combined with an ultracentrifugation technology, and animal experiments prove that a high-level IgG / IgM antibody can be induced by intramuscular injection of 50 micrograms per mouse, expression of inflammatory factors such as IL-6 and TNF-alpha of the spleen is remarkably improved, the protection rate after challenge reaches 85.7%, and pathological damage is remarkably lighter than that of an inactivated vaccine group. According to the scheme provided by the invention, the problems of insufficient serotype coverage and antibiotic resistance in the prior art are solved, and a new strategy is provided for prevention and control of mannheimia haemolytica.

The invention relates to a method of treating or preventing a disease or condition comprising administering a therapeutically effective amount of a psychedelic compound to a patient by intramuscular injection. Uses, formulations and kits are also described.

The invention relates to the technical field of animal husbandry, in particular to a synchronous oestrus-timing insemination method suitable for cattle, which comprises the following steps: firstly, performing intramuscular injection of PG (cloprostenol sodium) at different time points after calving to promote uterine recovery and luteolysis and lay a synchronous oestrus foundation; the method comprises the key steps that GnRH (gonadotropin release hormone) is given through intramuscular injection on the 43rd day, the 53rd day, the 60th day and the 69th day, pituitary is promoted to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collection and screening of follicles are guided, follicle maturation is promoted, the oestrus uncovering rate and the oestrus conception rate are increased, a melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day, and the melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day. The synthesis of ovarian hormones is promoted by regulating the hypothalamus-pituitary-gonad axis, the secretion of follicle cell factors and maturation promoting factors is promoted, the development of granular cells is promoted, and the maturation of oocytes is promoted. According to the method, the pregnancy rate of a double-synchronization-timing insemination scheme which is most widely used in a large-scale dairy cow breeding pasture at present can be remarkably increased, and feasible technical support is provided for success of increasing the breeding efficiency of cows.

The invention discloses a timed insemination method for improving the pregnancy rate and the lambing rate of sheep, and belongs to the technical field of livestock breeding. In order to solve the problem that the pregnancy rate of existing sheep is unstable during regular insemination, the method comprises the steps that a progesterone sponge suppository is embedded in the vagina of a healthy and reproductive ewe on the 0th day, and meanwhile 25 g of luteinizing hormone is injected in an intramuscular mode to release hormone A3; removing the thrombus on the 12th day, and performing intramuscular injection of 400IU of pregnant mare serum gonadotropin at the same time; and after the suppository is removed, insemination is carried out on the cervix orifice of the ewe with ram semen diluted at the ratio of 1: (5-8) in 52h and 64h respectively. According to the method, ovarian activities of the ewes are regulated and controlled, the estrus synchronism and the ovulation rate are improved, tests show that the pregnancy rate reaches 81.6%, the lambing rate is 1.14, compared with a conventional method, the pregnancy rate and the lambing rate of the sheep are remarkably improved, and development of the sheep industry is promoted.

The invention relates to medicine, in particular to gerontology and therapy and can be used for treating sarcopenia in elderly patients.Summary of the invention consists in alternating for 1…2 days the intravenous administration of ozonized 0.9% NaCl solution and major autohemotherapy, namely 500 mL of a 0.9% NaCl solution ozonized with an ozone-oxygen mixture, with an ozone concentration of 5…10 µg / mL, are administered, and major autohemotherapy consists in collecting 300…400 mL of venous blood from the patient, which is ozonized, with an ozone concentration of 15 µg / mL and transfused to the patient, the treatment course includes 8…10 consecutive procedures, then it is extended with minor autohemotherapy, which consists in collecting 5…10 mL of venous blood, which is ozonized, with an ozone concentration of 15 µg / mL and administered intramuscularly every 10th day of alternation and includes 3 consecutive procedures, and the ozonized 0.9% NaCl solution is administered for up to 6…8 weeks.

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

This invention provides a modified BoNT / A for treating facial wrinkles, wherein the modified BoNT / A is administered via intramuscular injection at multiple sites on an individual's face, wherein the modified BoNT / A is administered at a unit dose of greater than 1754 pg or greater than 8000 pg per site, wherein the multiple sites are selected from: up to two sites on the corrugator supercilii muscle and one site on the depressor supercilii muscle for treating glabellar lines; up to five sites on the frontalis muscle for treating forehead wrinkles; and up to three sites on the orbicularis oculi muscle for treating lateral canthal wrinkles, wherein the total dose of modified BoNT / A administered during treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N The structure domain), and the BoNT / B receptor binding domain (H C (structural domain).

The present invention relates to aqueous saline solutions comprising dantrolene and optionally at least one additional active ingredient, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic purposes. The solutions can be administered in any suitable manner, but have the advantage of being particularly well-suited for intramuscular injection.

Compounds comprising antiviral prodrugs, and pharmaceutical formulations comprising the compounds, which can be orally bioavailable or formulated for intramuscular injection. Methods for making compounds such as antiviral prodrugs. Methods for treating coronavirus and other RNA viral infections in mammals. Methods for producing pharmaceutical triphosphates.

The utility model relates to the technical field of syringe needle limiting parts, and discloses a stable muscle syringe needle limiting mechanism which comprises a supporting sleeve, a supporting plate and a syringe needle assembly, the supporting plate is arranged at the bottom of the supporting sleeve, and the syringe needle assembly is located on the inner side of the supporting sleeve and penetrates to the bottom of the supporting plate. An adjusting assembly is arranged on the outer side of the supporting sleeve, a limiting supporting assembly which is arranged on the outer side of the syringe needle assembly in a sleeving mode and fixedly connected with the adjusting assembly is arranged in the supporting sleeve, and a supporting movable assembly is arranged at the bottom of the supporting plate. According to the stable muscle syringe needle limiting mechanism, medical staff are allowed to adjust and lock the insertion depth of the syringe needle, the accuracy and safety of injection are improved, the stable muscle syringe needle limiting mechanism can adapt to syringe needles of different lengths, the supporting stability of the syringe needle limiting mechanism is improved, use convenience is improved, and the stable muscle syringe needle limiting mechanism is worthy of popularization and application. And the use of a user is facilitated.

The utility model belongs to the field of medical instruments, and particularly relates to a fulvestrant intramuscular injection positioning ruler which comprises a long fixed ruler, two short shifting rulers and two arc-shaped pieces, and the two short shifting rulers are located on the two sides of the long fixed ruler respectively and rotationally connected with the long fixed ruler; the two arc-shaped pieces are symmetrically distributed on the two sides of the long fixed ruler, one side of each arc-shaped piece is fixedly connected with the long fixed ruler, the other side of each arc-shaped piece is fixedly connected with the short shifting ruler, an arc-shaped notch is formed in the inner side of each arc-shaped piece, and a plurality of positioning holes are formed in each arc-shaped piece. The fulvestrant injection device is directly aligned with the highest point of iliac spine and the peak of hip fissure of a human body through the positioning rule in one step, compared with operation modes such as a cross method and a line connection method, the time for manual searching and positioning is saved, meanwhile, injection of fulvestrant is completed in the positioning hole, and the injection efficiency is improved. And injection errors and complications caused by non-professional operation methods, inaccurate manual positioning, repeated part injection and the like are solved, so that the injection pain of a patient is reduced, and the treatment compliance and the life quality are improved.

An embodiment of the present invention provides a biocompatible, thermosensitive hydrogel composition for subcutaneous or intramuscular injection, the hydrogel comprising a poloxamer, such as poloxamer 338, poloxamer 188, or poloxamer 407, or a mixture thereof, and the composition includes a therapeutic protein or antigen embedded in the composition for sustained release.

The present invention relates to aqueous compositions comprising dantrolene and optionally also at least one additional active principle, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic / cosmetic purposes. The compositions can be administered in any suitable way but are advantageous in that they are particularly well adapted to intramuscular injection, subcutaneous injection and / or intradermal injection.

The invention discloses a dexketoprofen trometamol nasal spray and a preparation method thereof, a buffering agent is used as a stabilizer, and the dexketoprofen trometamol nasal spray which is good in stability, small in irritation, convenient, rapid in effect taking and extremely small in side effect is provided, so that the medication compliance of patients and the convenience of clinical medication are improved; after being administrated, the nasal spray can be quickly absorbed through nasal mucosa, the absorption speed is equivalent to that of intramuscular injection, the nasal spray can quickly reach the peak concentration as intramuscular injection, and the curative effect can be quickly exerted; the preparation has the advantages of no first-pass effect during nasal mucosa administration, high bioavailability and rapid absorption, is suitable for self-rapid analgesia, and is stable in process and suitable for large-scale production.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The invention relates to the technical field of mRNA vaccine research and development, and discloses a Tp0136T cell epitope mRNA vaccine based on lipid nanoparticle delivery and application of the Tp0136T cell epitope mRNA vaccine in syphilis prevention, the vaccine contains an mRNA sequence and an LNP delivery system, the mRNA sequence contains a Tp0136T1T cell epitope coding region (amino acid L477-S486, optimized by codon), a Cap 1 structure, optimized UTR and poly (A) tails of 65-76 adenosine, and psi or m5C is used for replacing trona; the LNP is prepared from SM-102, DSPC (Distearoyl Pyrrolidone), cholesterol and DMG-PEG (Dimethyl Glycol-Polyethylene Glycol) according to a molar ratio of 50 The particle size of the vaccine is less than or equal to 150nm, PDIlt; 0.2, the Zeta potential is-5 to-15 mV, and the encapsulation efficiency is greater than or equal to 93.47%. The preparation method comprises the steps of mRNA design synthesis, mRNA-LNP preparation characterization and in-vitro expression verification, through intramuscular injection inoculation, strong Th1 type and CD8 + CTL immune response can be induced, treponema pallidum load and skin ulcer rate can be reduced, and the method can be used for syphilis prevention.

The application provides a kind of medicine composition for treating muscle and bone disease and its application, belong to medical technology field.The medicine composition includes the following weight parts components: compound angelica injection 5-10 parts, kadsura injection 5-10 parts, wild medlar injection 5-10 parts, methylcobalamin injection 5-10 parts;It can also be selectively added vitamin B1 injection, vitamin B12 injection, yellow Chinese wax injection or bone peptide injection.The composition of the application is administered by acupoint injection or intramuscular injection, utilizes the synergistic effect of multiple traditional Chinese medicine injection and western medicine injection, reaches the comprehensive treatment effect of promoting blood circulation to remove blood stasis, dispelling wind to stop pain, nerve nutrition.Clinical experiments show that the application has significant effect on lumbar disc herniation, cervical spondylosis, shoulder periarthritis, knee osteoarthritis, femoral head necrosis, osteoporosis and the like, and the total effective rate is more than 95%, with fast effect, low recurrence rate, and no hormone-related side effects, suitable for patients of all ages.

The application discloses a rat fixing device based on biological evaluation of medical instruments. The device comprises an operation panel, a fixing cover, a sliding sheet and a sliding groove. A rectangular opening is designed in the center of the base of the operation panel, which is specially used for abdominal cavity injection operation of rats. The rat fixing cover is divided into four sections and is arranged on the operation panel. The two sides of the fixing cover are provided with the sliding sheets. The shape of the two sliding sheets after being spliced together is the same as that of the fixing cover. The lower end of the sliding sheet is in contact with the operation panel, and the sliding groove is arranged at the contact part. The rat fixing device can effectively adjust the size, so that rats with different body types can be effectively fixed, and the smooth operation of the test is ensured. The device is convenient to operate and stable in rat fixing.

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

Briefly, an injection delivery system is described for subcutaneous or intramuscular injection of a drug, in particular a large volume of a biologic drug, high and low viscosity biologies, or a large volume of a high viscosity and low viscosity chemical drug. The injections may be self-administered or performed by a caregiver. The system uses a pump to move a drug from a vial, thorough an infusion set, and into the patient. A vial of a biological or chemical drug is set into a vial adapter that is associated with the pump, which can be manual or powered. A fluidics subassembly connects the vial adapter, pump, and the infusion set so that a drug pathway is enabled from the vial to the patient. The fluidics subassembly has one or more check valves to assure that the drug pathway is only enabled for a one-way drug flow out of the vial and to the patient. The infusion set has flexible tubing that connects the fluidics subassembly to cannula assembly inside an infuser housing. The cannula assembly has an air evacuation assembly near the tip of the needle. This air evacuation assembly is constructed to safely exhaust air from the cannula assembly at three times: (1) at initial setup to exhaust air while the drug is filling the cannula assembly, which enables the self-priming; (2) during injection to exhaust drug-entrapped air, which increases injection safety; and (3) at the end of drug delivery to exhaust air after the full dose of drug has been delivered to the cannula assembly, including drug that was in the tubing, which reduces wasted drug and minimizes the amount of drug overfill required in the vial.

This invention discloses a PKPD-guided method for treating porcine Pasteurella multocida with antibiotics. YDMS injection is used as the antibiotic, administered intramuscularly to pigs infected with Pasteurella multocida. The dosing regimen is adjusted based on in vivo PK / PD target values. The minimum inhibitory concentration (MIC) of YDMS against Pasteurella multocida is 0.06 μg / mL. PK / PD monitoring is performed using a combination of colloidal gold rapid detection and quantitative real-time PCR. This invention clarifies the three-level PK / PD target values ​​of YDMS against Pasteurella multocida and uses AUIC as the core quantitative indicator, avoiding the blindness of traditional empirical dosing. This ensures precise matching of drug concentration and infection severity, effectively reducing the risk of infection aggravation due to insufficient medication or cumulative toxicity caused by overdose, and significantly improving the consistency of treatment efficacy.

The utility model relates to the technical field of injectors, in particular to a clinical intramuscular injection universal injector which comprises an injection sleeve, a needle head arranged at one end of the injection sleeve, a piston connected to the injection sleeve in a sliding mode, a push rod with one end extending into the injection sleeve to be connected with the piston and a push head arranged at the end of the push rod. The fixed sleeve is fixed to the injection sleeve, the movable sleeve is detachably connected to the fixed sleeve, one end of each support is connected with the movable sleeve, the three supports are arranged in a triangular shape, and when two thirds of the needle head is inserted into the human body, the bottom ends of the three supports abut against the skin of the human body; according to the intramuscular injection needle, the insertion depth of the needle head can be guaranteed, the needle head can be effectively prevented from being continuously immersed into the skin in the propelling injection process, the situation that the injection position is inclined is avoided, the difficulty of clinical intramuscular injection is reduced, and the intramuscular injection effect is guaranteed.

To provide a PARP1 inhibitor and its use.SOLUTION: PARP1 inhibitors and pharmaceutical compositions comprising such inhibitors are described herein. The subject compounds and compositions are useful for the treatment of cancer. The compounds described herein are administered to a subject in need thereof according to standard pharmaceutical practice, either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition. In one embodiment, the compounds of the invention can be administered to an animal. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.SELECTED DRAWING: None

The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

The present application relates to a composition using an endothelin B receptor agonist, such as Sovastatin (N-succinyl-[Glu9, Ala11, 15] endothelin 1, IRL-1620), for promoting cell proliferation and protecting the original neuroepithelium of cochlear and vestibular cells located within the ear sac. The pharmaceutical composition is systemically administered by means of tympanic membrane puncture, cochleostomy or intravenous or intramuscular injection. A pharmaceutical composition for the treatment of sensorineural hearing loss and vestibular disorders caused by inner ear cell degeneration, the pharmaceutical composition comprising a compound of an endothelin analogue, the use being treated by the neuroprotection and neurogenesis mechanism of cochlear vestibular hair cells and synapses.

The invention relates to a long-acting sustained-release pharmaceutical preparation and a preparation method thereof, the long-acting sustained-release pharmaceutical preparation is a microsphere preparation, the microsphere comprises brexpiprazole and PLGA, the content of the brexpiprazole is 45%-75% of the total weight of the microsphere, and the content of the PLGA is 55%-25% of the total weight of the microsphere; the viscosity of the PLGA is 0.15 to 0.25 dl / g, and the molecular weight of the PLGA is 8000 to 32000. The microsphere is high in drug loading capacity, the administration dosage can be effectively reduced, subcutaneous or muscle administration pain of a patient is reduced, the prepared sustained-release microsphere has no burst release phenomenon, and the change of the blood concentration in an effective release period in a rat is stable.

The application discloses a recombinant adenovirus vector tumor vaccine and a preparation method and application thereof, wherein the antigen coded by the recombinant adenovirus vector tumor vaccine comprises any one or a combination of more than two antigen peptide epitopes of KRAS protein. The recombinant adenovirus vector tumor vaccine of the application codes multiple KRAS tumor-specific antigen peptides, and has a good killing effect on KRAS mutation-driven tumors, especially lung tumors. The vaccine can be inhaled in a form of atomization, injected into muscles first and then inhaled in a form of atomization, inhaled in a form of atomization first and then injected into muscles, injected into muscles, or simultaneously injected into muscles and administered in a form of atomization. After atomization, the vaccine can be inhaled through a nasal cavity or an oral cavity to reach the lungs, generate an anti-tumor protective immune response on the respiratory tract, the lungs and the whole body, and enhance the utilization rate and the treatment effect of the vaccine.

The invention relates to the technical field of aquaculture and biology, in particular to an SIFamide neuropeptide gene and application of the SIFamide neuropeptide gene in promoting growth of litopenaeus vannamei. The litopenaeus vannamei SIFamide gene is shown as a nucleotide sequence of SEQ ID NO: 1. The SIFamide neuropeptide gene is applied to the growth and intestinal peristalsis of the litopenaeus vannamei. The nucleotide sequence of the interference fragment for inhibiting the SIFamide neuropeptide gene is as shown in SEQ ID NO: 4. After the nucleotide sequence (double-stranded RNA) of the interference fragment is applied to the litopenaeus vannamei in an intramuscular injection manner, the weight increase of the litopenaeus vannamei is obviously accelerated and the intestinal peristalsis frequency is obviously improved under the condition that the expression of the SIFamide gene is inhibited. According to the method, damage to the litopenaeus vannamei is small, normal ingestion, molting, inhabiting and other behaviors of the litopenaeus vannamei are not affected, and the action effect is stable.

The invention relates to an automatic subcutaneous insulin injection device for the endocrinology department. The automatic subcutaneous insulin injection device comprises a rack, an arm fixing module, an automatic injection module, a driving module and a main control module. The arm fixing module is provided with an adjustable supporting seat and a fixing belt and is used for being matched with arms of different patients. The automatic injection module adopts a pneumatic design, and a negative pressure hole in a needle can adsorb skin to form wrinkles, so that intramuscular injection is avoided; the first pneumatic telescopic piece drives the needle cylinder to pierce subcutaneously, and the second pneumatic telescopic piece pushes the piston to complete injection. The driving module controls overall lifting, and the main control module coordinates all actions. The device realizes automation and standardization of arm insulin injection, is safe and efficient to operate, and is suitable for a clinical environment.